RESUMEN
In both adjuvant arthritis and rheumatoid arthritis, edema and inflammation appear in synovial joints. Edema or effusion reflects an imbalance in lymph dynamics. Purified micronized flavonoid fraction is mainly used in the treatment of chronic venous insufficiency. This compound improves lymphatic drainage with a significant increase in lymphatic flow and lymphatic pulsality. It is suggested that the beneficial effect of purified micronized flavonoid fraction may be involved in the treatment of adjuvant arthritis in rats. In this study treatment of adjuvant arthritis in rats with Detralex, methotrexate, and their combination were evaluated. Groups of rats with adjuvant arthritis were treated with methotrexate (0.6 mg/kg/week), Detralex (20 mg/kg/day), and their combination for 50 days from adjuvant application. Hind paw swelling, arthrogram scores, serum albumin level, serum nitrite/nitrate concentrations, and whole-body mineral density were evaluated as markers of inflammation and destructive changes associated with arthritis. Long-term prophylactic treatment with low-dose methotrexate significantly inhibited the markers of both inflammation and arthritis. Detralex administered alone slightly decreased both the hind paw swelling and the arthritic score. Other inflammatory and arthritic markers were not significantly influenced. However, Detralex combined with methotrexate markedly potentiated the beneficial effects of methotrexate, which resulted in a more significant reduction in hind paw swelling, arthritic scores, and serum concentrations of nitrite/nitrate. Interestingly, the arthritis-induced decrease of bone mineral density in AA rats was significantly lower only in the group treated with the combination of Detralex and methotrexate. Our results indicate that Detralex increased the therapeutic efficacy of methotrexate basal treatment in AA. We suggest that this may be related to the beneficial effect of Detralex on microcirculation, especially on venules and lymphatic vessels.
Asunto(s)
Artritis Experimental/tratamiento farmacológico , Diosmina/uso terapéutico , Hesperidina/uso terapéutico , Metotrexato/uso terapéutico , Animales , Artritis Experimental/sangre , Artritis Experimental/patología , Combinación de Medicamentos , Sinergismo Farmacológico , Quimioterapia Combinada , Miembro Posterior/efectos de los fármacos , Miembro Posterior/patología , Inmunosupresores/uso terapéutico , Masculino , Nitratos/sangre , Nitritos/sangre , Ratas , Ratas Endogámicas Lew , Albúmina Sérica/metabolismo , Resultado del TratamientoRESUMEN
OBJECTIVES: The acute toxicity of magnetic nanoparticles was effectively lowered by their encapsulation with poly(D,L lactide). In relation to the idea to use magnetic nanoparticles in development of new delivery systems suitable for targeted drug administration, the toxicological profile of five types of magnetic fluids was assessed in mice. METHODS: The nanoprecipitation method was used to prepare magnetic fluids containing nanoparticles of Fe(3)O(4) encapsulated with biodegradable substances. The acute toxicity testing was performed according to OECD Test Guideline 425. In the pilot distribution study a special staining method was examined for the detection of Fe ions in body tissues of mice after intravenous administration of magnetic fluids. RESULTS: The p.o. LD(50) values were greater than 2,000.0 mg/kg of body weight and i.v. LD(50) values were in the range of 231.7-558.9 mg/kg of body weight. CONCLUSIONS: Of the magnetic nanoparticles tested, those encapsulated with poly(D,L lactide) were the most prospective for further in vivo testing.
Asunto(s)
Nanopartículas del Metal/toxicidad , Animales , Composición de Medicamentos , Femenino , Magnetismo , Nanopartículas del Metal/análisis , Ratones , Ratones Endogámicos ICR , Poliésteres/química , Pruebas de ToxicidadAsunto(s)
Arteritis de Células Gigantes/sangre , Arteritis de Células Gigantes/complicaciones , Enfermedades del Nervio Oculomotor/etiología , Polimialgia Reumática/etiología , Anciano , Sedimentación Sanguínea , Humanos , Masculino , Enfermedades del Nervio Oculomotor/sangre , Polimialgia Reumática/sangreRESUMEN
OBJECTIVE: Red wine polyphenols have been reported to possess beneficial properties for preventing cardiovascular diseases but their effects on hemodynamic and functional cardiovascular changes during inhibition of nitric oxide (NO) synthesis have not been elucidated. DESIGN: The effects of the red wine polyphenols, Provinols, on arterial hypertension as well as left ventricular (LV) hypertrophy, myocardial fibrosis and vascular remodeling were investigated in rats during chronic inhibition of nitric oxide synthase (NOS) activity. Rats were divided into four groups: a control group, a group treated with N-nitro-L-arginine methyl ester (L-NAME) (40 mg/kg per day), a group receiving Provinols (40 mg/kg per day) alone or Provinols plus L-NAME. RESULTS: Provinols markedly reduced the increase in both blood pressure and protein synthesis in the heart and aorta caused by chronic inhibition of NO synthesis. Provinols reduced myocardial fibrosis even though it did not affect LV hypertrophy. In addition, Provinols prevented aortic thickening and corrected the augmented reactivity of the aorta to norepinephrine and the attenuated endothelium-dependent relaxation to acetylcholine in NO-deficient rats. These alterations were associated with an increase of NOS activity, a moderate enhancement of endothelial NOS expression and a reduction of oxidative stress in the LV and aorta. CONCLUSION: Our results provide evidence that Provinols partially prevents L-NAME-induced hypertension, cardiovascular remodeling and vascular dysfunction via the increase of NO-synthase activity and prevention of oxidative stress. Thus, the beneficial effects of plant polyphenols in prevention of hypertension may result from their complex influence on the NO balance in the cardiovascular system.
Asunto(s)
Enfermedades de la Aorta/prevención & control , Flavonoides/farmacología , Hipertensión/complicaciones , Hipertrofia Ventricular Izquierda/prevención & control , Fenoles/farmacología , Vino , Alcadienos/metabolismo , Animales , Enfermedades de la Aorta/etiología , Enfermedades de la Aorta/patología , Presión Sanguínea/efectos de los fármacos , Western Blotting , Radioisótopos de Carbono , Inhibidores Enzimáticos , Hipertensión/inducido químicamente , Hipertensión/patología , Hipertrofia Ventricular Izquierda/etiología , Hipertrofia Ventricular Izquierda/patología , Leucina/farmacocinética , Masculino , Miocardio/patología , NG-Nitroarginina Metil Éster , Óxido Nítrico/metabolismo , Óxido Nítrico Sintasa/antagonistas & inhibidores , Norepinefrina/farmacología , Polifenoles , Ratas , Ratas Wistar , Vasoconstrictores/farmacologíaRESUMEN
Histopathological evaluation of the mammary gland tumours of Sprague-Dawley rats induced with 1-methyl-1-nitrosourea (MNU), and treated with either CpG oligodeoxynucleotides (CpG-ODN) and/or 13-cis retinoic acid has been performed in this work. Since, the treatment of animals with CpG-ODN induced a significant decrease of tumour burden and volume in comparison with MNU treated control group (Macejova et al. 2001), it was of high impact to compare histological appearance of tumours in different experimental groups (MNU, CpG-ODN, 13-cis retinoic acid, CpG-ODN plus 13-cis retinoic acid). We have found reduced number of carcinomas with necroses in the CpG motifs treated group when compared to animals treated with MNU only. From the histological point of view the treatment with the CpG-ODN may have some protective effect. Carcinoma patterns proportion in the group treated with CpG-ODN was found to be different in comparison with other experimental groups. Treatment of rats with CpG-ODN had no apparent effect on invasiveness of developed carcinomas.
Asunto(s)
Adenocarcinoma/tratamiento farmacológico , Adyuvantes Inmunológicos/uso terapéutico , Islas de CpG , Isotretinoína/uso terapéutico , Neoplasias Mamarias Experimentales/tratamiento farmacológico , Oligodesoxirribonucleótidos/uso terapéutico , Adenocarcinoma/etiología , Adenocarcinoma/patología , Animales , Modelos Animales de Enfermedad , Quimioterapia Combinada , Femenino , Neoplasias Mamarias Experimentales/etiología , Neoplasias Mamarias Experimentales/patología , Metilnitrosourea/toxicidad , Ratas , Resultado del TratamientoRESUMEN
The effects of the red wine polyphenolic compounds (Provinol) on hypertension, left ventricular hypertrophy, myocardial fibrosis, and vascular remodeling were investigated after chronic inhibition of nitric oxide (NO) synthase by administration of N(G)-nitro-L-arginine methyl ester (L-NAME) to rats. Rats were divided into four groups: a control group, a group treated for 4 wk with L-NAME (40 mg x kg(-1) x day(-1)), and two groups treated with L-NAME followed by 3 wk of either spontaneous recovery or recovery with Provinol treatment (40 mg x kg(-1) x day(-1)). Administration of Provinol produced a greater readiness of the decrease in blood pressure than that in the spontaneous recovery group. Provinol significantly depressed myocardial fibrosis and expedited the decrease in aortic cross-sectional area, the increase in endothelium-dependent relaxation, and the decrease in contraction of the aorta. These effects of Provinol were associated with a greater increase of NO synthase activity in the left ventricle and the aorta. The present study provides evidence that Provinol accelerates the regression of blood pressure and improves structural and functional cardiovascular changes produced by chronic inhibition of NO synthesis.